Aurinia Pharmaceuticals(FRA) IKAP

Market Cap€1.86B

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

€13.77

-1.57%

-0.22Today

Aurinia Pharmaceuticals Financials at a Glance

Market Cap

€1.86B

Revenue (TTM)

€267.11

Net Income (TTM)

€269.65

EPS (TTM)

€1.96

P/E Ratio

7.12

Dividend

€0.00

Beta (Volatility)

0.10 (Low)

Dividend

€0.00

Beta (Volatility)

0.10 (Low)

Price

€13.77

Volume

Open

€13.78

Price

€13.77

Volume

Open

€13.78

Previous Close

€13.77

Daily Range

€13.77 - €13.78

52-Week Range

€9.34 - €16.40

Estimated Earnings Date

N/A

Dividend

€0.00

Beta (Volatility)

0.10 (Low)

Price

€13.77

Volume

Open

€13.78

Previous Close

€13.77

Daily Range

€13.77 - €13.78

52-Week Range

€9.34 - €16.40

Estimated Earnings Date

N/A

IKAP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Industry

Biotechnology

Sector

Health Care

Employees

128

CEO

Kevin C. Tang

Website

www.auriniapharma.com

IKAP Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

65.49%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

14.04%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€1.86B

Shares Outstanding

133.05M

Volume

Avg. Volume

16.455

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Aurinia Pharmaceuticals Performance Analysis

Aurinia Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 127,529,282	230.5%
2023	2023-12-31	EUR 162,344,341	27.3%
2024	2024-12-31	EUR 217,375,436	33.9%
2025	2025-12-31	EUR 250,806,778	15.4%

Aurinia Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR -0.73	-38.7%
2023	2023-12-31	EUR -0.50	-30.5%
2024	2024-12-31	EUR 0.04	N/A
2025	2025-12-31	EUR 1.83	4940.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

€71.57

+1.2%

Gross Profit

€65.94

+1.2%

Gross Margin

92.12%

+1.0%

Market Cap

€1.86B

N/A

Market Cap/Employee

€14.58

N/A

Employees

128

N/A

Net Income

€32.18

+1.7%

EBITDA

€38.65

+1.3%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

€213.39

+85.8%

Total Debt

€56.10

+0.8%

Accounts Receivable

€35.98

+1.1%

Inventory

€39.49

+1.0%

Long Term Debt

€40.19

+0.7%

Short Term Debt

€15.90

+1.1%

Return on Assets

48.10%

+4.0%

Return on Invested Capital

-6.33%

+0.3%

Free Cash Flow

€45.04

+1.1%

Operating Cash Flow

€45.04

+1.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About IKAP

What is the current price of Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals is trading at €13.77 per share.

What is the 52-week range for Aurinia Pharmaceuticals?

Over the past 52 weeks, Aurinia Pharmaceuticals has traded between €9.34 and €16.40.

How much debt does Aurinia Pharmaceuticals have?

As of the most recent reporting period, Aurinia Pharmaceuticals reported total debt of €56.10M.

How much cash does Aurinia Pharmaceuticals have on hand?

Aurinia Pharmaceuticals reported €157.29M in cash and cash equivalents in its most recent financial results.

What is Aurinia Pharmaceuticals’s dividend yield?

Aurinia Pharmaceuticals does not currently have a dividend yield.

Aurinia Pharmaceuticals(FRA) IKAP

Aurinia Pharmaceuticals Financials at a Glance

IKAP News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Aurinia Pharmaceuticals

IKAP Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Aurinia Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IKAP

What is the current price of Aurinia Pharmaceuticals?

What is the 52-week range for Aurinia Pharmaceuticals?

How much debt does Aurinia Pharmaceuticals have?

How much cash does Aurinia Pharmaceuticals have on hand?

What is Aurinia Pharmaceuticals’s dividend yield?

Premium Investing Services